Is Biosyent Inc. a Buy? The Stock Rises Again

 Is Biosyent Inc. a Buy? The Stock Rises Again

The stock of Biosyent Inc. (CVE:RX) is a huge mover today! About 7,300 shares traded hands or 47.36% up from the average. Biosyent Inc. (CVE:RX) has risen 6.00% since October 15, 2016 and is uptrending. It has outperformed by 1.02% the S&P500.
The move comes after 8 months positive chart setup for the $114.09M company. It was reported on Nov, 14 by Barchart.com. We have $11.11 PT which if reached, will make CVE:RX worth $43.35M more.

More news for Biosyent Inc. (CVE:RX) were recently published by: Midasletter.com, which released: “Small Cap Discoveries Editor Paul Andreola on Lingo Media Corp, Biosyent Inc …” on January 19, 2016. Seekingalpha.com‘s article titled: “BioSyent: A Great Micro Cap” and published on October 28, 2013 is yet another important article.

BioSyent Inc. is a specialty pharmaceutical company. The company has a market cap of $114.09 million. The Company, through its subsidiary, BioSyent Pharma Inc., acquires or in-licenses and develops pharmaceutical products for sale in Canada and certain international markets. It has a 29.75 P/E ratio. It has four business units: the Community and Women’s Health Unit, which commercializes pharmaceutical products focused on improving family and women’s health; the Hospital Business Unit, which sells pharmaceutical products to hospitals and hospital specialists; the International Pharmaceutical Unit, and the Legacy Business.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment